39.28
Atricure Inc stock is traded at $39.28, with a volume of 209.17K.
It is up +1.58% in the last 24 hours and down -0.87% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
See More
Previous Close:
$38.74
Open:
$38.71
24h Volume:
209.17K
Relative Volume:
0.44
Market Cap:
$1.85B
Revenue:
$447.57M
Net Income/Loss:
$-38.92M
P/E Ratio:
-47.32
EPS:
-0.83
Net Cash Flow:
$-1.15M
1W Performance:
+0.42%
1M Performance:
-0.87%
6M Performance:
+51.71%
1Y Performance:
+8.47%
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ATRC
Atricure Inc
|
39.28 | 1.85B | 447.57M | -38.92M | -1.15M | -0.83 |
![]()
ISRG
Intuitive Surgical Inc
|
576.94 | 205.74B | 8.35B | 2.32B | 1.30B | 6.41 |
![]()
BDX
Becton Dickinson Co
|
228.86 | 65.11B | 20.64B | 1.73B | 2.94B | 6.02 |
![]()
ALC
Alcon Inc
|
94.57 | 46.26B | 9.91B | 1.02B | 665.00M | 2.05 |
![]()
RMD
Resmed Inc
|
234.76 | 34.51B | 4.93B | 1.25B | 1.38B | 8.47 |
![]()
COO
The Cooper Companies, Inc.
|
92.39 | 18.19B | 3.90B | 392.30M | 288.10M | 1.95 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-17-24 | Resumed | JP Morgan | Overweight |
Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
Sep-29-23 | Initiated | UBS | Buy |
Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-18-20 | Reiterated | Needham | Buy |
Nov-06-20 | Reiterated | Needham | Buy |
Apr-07-20 | Initiated | Oppenheimer | Outperform |
Feb-06-20 | Initiated | BTIG Research | Buy |
Jan-24-20 | Reiterated | Needham | Buy |
Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
Apr-12-19 | Initiated | JP Morgan | Overweight |
Oct-04-18 | Reiterated | Needham | Buy |
Aug-02-18 | Reiterated | Needham | Buy |
Aug-02-18 | Reiterated | Stifel | Buy |
Jun-18-18 | Reiterated | Needham | Buy |
Apr-27-18 | Reiterated | Needham | Buy |
Jan-16-18 | Reiterated | Needham | Buy |
Nov-02-17 | Reiterated | Needham | Buy |
Jul-28-17 | Reiterated | Needham | Buy |
May-30-17 | Resumed | Piper Jaffray | Overweight |
Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
Oct-28-15 | Reiterated | Needham | Buy |
Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
AtriCure, Inc. to Host Earnings Call - ACCESS Newswire
26,035 Shares in AtriCure, Inc. (NASDAQ:ATRC) Acquired by AlphaCentric Advisors LLC - MarketBeat
HighMark Wealth Management LLC Has $2.56 Million Holdings in AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
Short Interest in AtriCure, Inc. (NASDAQ:ATRC) Declines By 20.4% - MarketBeat
AtriCure, Inc. (NASDAQ:ATRC) Q4 2024 Earnings Call Transcript - MSN
Stifel Nicolaus Raises AtriCure (NASDAQ:ATRC) Price Target to $48.00 - MarketBeat
AtriCure (NASDAQ:ATRC) Price Target Raised to $45.00 at Oppenheimer - MarketBeat
AtriCure (NASDAQ:ATRC) Stock Price Down 5.8%Here's What Happened - MarketBeat
AtriCure (NASDAQ:ATRC) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Canaccord Genuity Group Forecasts Strong Price Appreciation for AtriCure (NASDAQ:ATRC) Stock - MarketBeat
AtriCure (NASDAQ:ATRC) Announces Earnings Results - MarketBeat
AtriCure (ATRC) Expected to Announce Earnings on Thursday - MarketBeat
AtriCure's (ATRC) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
AtriCure targets $517M-$527M revenue in 2025 with new product launches and international growth - MSN
Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS - MSN
(ATRC) Technical Pivots with Risk Controls - Stock Traders Daily
AtriCure (NASDAQ:ATRC) Price Target Raised to $51.00 at JPMorgan Chase & Co. - MarketBeat
Atricure Files For Mixed Shelf; Size Not DisclosedSEC Filing -February 14, 2025 at 03:53 pm EST - Marketscreener.com
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know - MSN
AtriCure Inc. (ATRC) reports earnings - Quartz
AtriCure, Inc. SEC 10-K Report - TradingView
WCM Investment Management LLC Sells 23,785 Shares of AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
Silver Oak Securities Incorporated Invests $220,000 in AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
Earnings call transcript: AtriCure Q4 2024 revenue rises, stock dips By Investing.com - Investing.com Australia
AtriCure’s Earnings Call Highlights Strong Growth and Positive Outlook - TipRanks
AtriCure (NASDAQ:ATRC) Earns Market Outperform Rating from JMP Securities - MarketBeat
AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: AtriCure Q4 2024 revenue rises, stock dips - MSN
AtriCure price target raised to $57 from $53 at BTIG - TipRanks
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
AtriCure price target raised to $48 from $36 at Stifel - TipRanks
IAC, AtriCure, and Astera Labs: Top Stock Picks for Growth in 2025 - PUNE.NEWS
AtriCure price target raised to $66 from $61 at Canaccord - TipRanks
AtriCure price target raised to $50 from $40 at Piper Sandler - TipRanks
AtriCure Inc (ATRC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
AtriCure, Inc. Reports Strong 2024 Financial Growth - TipRanks
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):